Clarity’s COBRA Study Selected as a Top-Rated Oral Presentation at Prestigious Industry Annual Meeting

• Two abstracts outlining Clarity’s latest SAR-bisPSMA data have been accepted to be presented at the upcoming European Association of Nuclear Medicine (EANM) 2024 Congress on the 19-23 October.
• Abstracts on the diagnostic clinical trial, COBRA, and a theranostic case report (complete response in a patient with metastatic castrate-resistant prostate cancer [mCRPC]) were accepted for oral presentation.
• The COBRA abstract was selected as a Top-Rated Oral Presentation within the Scientific Programme (Oncology & Theranostic) of the EANM 2024 Congress.

Clarity’s Executive Chairperson, Dr Alan Taylor, commented, “We are very excited about the trajectory of development for our optimised prostate-specific membrane antigen (PSMA) targeting agent, SAR-bisPSMA, for both imaging and therapy. The EANM Congress is one of the most prestigious conferences in nuclear medicine, and it is fantastic to receive this recognition from our industry. SAR-bisPSMA, built at the benchtop of Australian science, was constructed after thoroughly understanding the limitations of first-generation PSMA targeting molecules, and with the use of some novel chemistry, we were able to overcome these limitations by increasing the uptake and retention of this molecule in prostate cancer. The abstracts accepted for presentation highlight the exciting possibilities of our SAR-bisPSMA product, uniquely positioned for this molecule to become best in class for both the treatment and diagnosis/staging of cancer."

“We are excited to share this remarkable data as we continue to adhere to the highest standards of clinical research, work with world-class clinical sites and generate promising results, while continuously expanding the platform into new indications, targeting high unmet need in the oncology field, so that we can positively impact outcomes for patients in need of innovative treatment options.

“The COBRA results showed that 64Cu-SAR-bisPSMA was able to detect prostate cancer lesions in patients in biochemical recurrence (BCR) of prostate cancer, who had a negative or equivocal standard of care scan at study entry. The study was selected as a Top-Rated Oral Presentation, which underscores the strength of the data and the potentially transformative clinical impact of 64Cu-SAR-bisPSMA in the BCR setting. Regarding our theranostic platform, the case report highlights the potential of 67Cu-SAR-bisPSMA to treat patients with mCRPC. It describes the case of a heavily pre-treated patient who achieved a complete response (anatomical, molecular and biochemical) following 2 cycles of 67Cu-SAR-bisPSMA (8 GBq per cycle). We look forward to further developing our existing and novel Targeted Copper Theranostic (TCT) products and continuing to provide better treatment options for children and adults with cancer.”